Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial.
Guest, R Kirillova, N Mowbray, S Gornall, Hannah Rothwell, Dominic G Cheadle, Eleanor J Austin, E Smith, K Watt, S Kühlcke, K
Guest, R
Kirillova, N
Mowbray, S
Gornall, Hannah
Rothwell, Dominic G
Cheadle, Eleanor J
Austin, E
Smith, K
Watt, S
Kühlcke, K
Citations
Altmetric:
Abstract
Adoptive cell therapy employing gene-modified T-cells expressing chimeric antigen receptors (CARs) has shown promising preclinical activity in a range of model systems and is now being tested in the clinical setting. The manufacture of CAR T-cells requires compliance with national and European regulations for the production of medicinal products. We established such a compliant process to produce T-cells armed with a first-generation CAR specific for carcinoembryonic antigen (CEA). CAR T-cells were successfully generated for 14 patients with advanced CEA(+) malignancy. Of note, in the majority of patients, the defined procedure generated predominantly CD4(+) CAR T-cells with the general T-cell population bearing an effector-memory phenotype and high in vitro effector function. Thus, improving the process to generate less-differentiated T-cells would be more desirable in the future for effective adoptive gene-modified T-cell therapy. However, these results confirm that CAR T-cells can be generated in a manner compliant with regulations governing medicinal products in the European Union.
Description
Date
2014-02
Publisher
Collections
Keywords
Type
Article
Citation
Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial. 2014, 63 (2):133-45 Cancer Immunol Immunother